Regulatory snapshots, including drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations in Asia-Pacific, including: Akebia, Ascentage, Astellas, Biontech, Cansino, Celltrion, Chemrar, Glaxosmithkline, Horizon, Incyte, Insmed, JCR, Merck, Mezzion, Pfizer, RDIF, Samsung Bioepis, Seagen, Shanghai Henlius, Takeda, Union, Vertex, Vir.

Clinical updates from Asia, including trial initiations, enrollment status and data readouts and publications, including: Angion Biomedica, Astrazeneca, Clover, Cynata, Daiichi Sankyo, Durect, Dynavax, Eirgenix, Eli Lilly, Foresee, Glaxosmithkline, Gritstone Oncology, Humanigen, Hutchison China Meditech, Incyte, KM Biologics, Marinomed, Neurorx, Omeros, Pfizer, Regeneron, Revive, Shanghai Henlius, Vasomune, Vir.

Biopharma happenings in Asia-Pacific, such as deals and partnerships, grants, preclinical data and other news in brief, including: Ajinomoto, Allianthera, Ascentage, Biontech, Bright Peak, CDC, Cerecor, Cipla, Clinuvel, Curevac, Evelo, Exagen, Fairjourney Biologics, Hoth, Hutchison China Meditech, Immunoprecise Antibodies, Insilico Medicine, Iontas, Johnson & Johnson, Kaleido, Kazia, Kyowa Kirin, Menarini, Mitsubishi Tanabe, Moderna, Neurobo, Nippon Shinyaku, Nobelpharma, Novadiscovery, Open Orphan, Pfizer, Pierre Fabre, Probiogen, RDIF, Sanofi, Siga Technologies, Simcere, Takeda, Twist, Y-Biologics, Zenas.

New hires and promotions in the biopharma industry in Asia-Pacific, including: Beigene, PYC Therapeutics.

Biopharmas in Asia-Pacific raising money in public or private financings, including: Bioheng, Brii, Qihan, Sunshine, Universe.

HONG KONG – Otsuka Pharmaceutical Co. Ltd. is celebrating its 100th anniversary by inking a collaboration and licensing agreement with Perception Neuroscience LLC to develop and commercialize the latter’s PCN-101 (r-ketamine) in Japan.